BuzzSparks.org

Ambit Biosciences


Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit’s lead compound,...

Founded in 2000
Homepage:
Total money raised: $109.3M

92121 4215 Sorrento Valley Blvd.

San Diego
USA CA

Phone: 858-334-2100

Updated on Aug 26, 2013
Ambit Biosciences at CrunchBase
Faheem Hasnain Board Chairman
Michael A. Martino President & CEO
Alan Lewis President & CEO
Athena Countouriotis Chief Medical Officer
Alan Fuhrman CFO
Christopher J. Morl COO
Steven A. Elms Board Director
Allan P. Marchington Board Director
Isai Peimer Board Director
David Bonita Board Director
Standish M. Fleming Board Director
David R. Parkinson Board Director
Joseph Regan Board Director
Past

November, 2012

Ambit Biosciences raised $22.2M in a Series E round

SEC    sec.gov

Ambit Biosciences raised $50M in unattributed round from OrbiMed Advisors, Aisling Capital, Apposite Capital, Roche Venture Fund, GrowthWorks Capital, MedImmune Ventures, Forward Ventures, Gimv, and Radius Ventures

Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia    finance.yahoo.com

May, 2012

Ambit Biosciences raised $7.1M in partial round

SEC    sec.gov

June, 2011

Ambit Biosciences raised $30M in a Series D round from Apposite Capital, OrbiMed Advisors, Forward Ventures, Roche Venture Fund, MedImmune Ventures, Gimv, GrowthWorks Capital, Radius Ventures, NovaQuest, and Horizon Technology Finance Management LLC

AMBIT BIOSCIENCES COMPLETES $30 MILLION SERIES D-2 FINANCING    ambitbio.com

2000

Ambit Biosciences was founded in 2000